1. 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. (9th November 2020) Authors: Ascierto, Paolo; Lewis, Karl; Robert, Caroline; Stroyakovskiy, Daniil; Gogas, Helen; Protsenko, Svetlana; Pereira, Rodrigo; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Li, Haocheng; Zhu, Qian; McKenna, Edward; McNally, Virginia; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020) Authors: Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020) Authors: Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Issue 4 (April 2018) Authors: Maio, Michele; Lewis, Karl; Demidov, Lev; Mandalà, Mario; Bondarenko, Igor; Ascierto, Paolo A; Herbert, Christopher; Mackiewicz, Andrzej; Rutkowski, Piotr; Guminski, Alexander; Goodman, Grant R; Simmons, Brian; Ye, Chenglin; Yan, Yibing; Schadendorf, Dirk Journal: Lancet oncology Issue: Volume 19:Issue 4(2018) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10240 (13th June 2020) Authors: Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A; Ascierto, P... Journal: Lancet Issue: Volume 395:Issue 10240(2020) Page Start: 1835 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Issue 4 (April 2017) Authors: Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Fo... Journal: Lancet oncology Issue: Volume 18:Issue 4(2017:Apr.) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Issue 9 (September 2016) Authors: Ascierto, Paolo A; McArthur, Grant A; Dréno, Brigitte; Atkinson, Victoria; Liszkay, Gabrielle; Di Giacomo, Anna Maria; Mandalà, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Yan, Yibing; Wongchenko, Matthew; Chang, Ilsung; Hsu,... Journal: Lancet oncology Issue: Volume 17:Issue 9(2016:Sep.) Page Start: 1248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies. Issue 1 (29th June 2020) Authors: Zhang, Weijiang; Mathisen, Michael; Goodman, Grant R.; Forbes, Harper; Song, Yuyao; Bertran, Enric; Demidov, Lev; Shin, Sang Joon Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 1(2021) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy. (12th April 2018) Authors: Zhang, Weijiang; McIntyre, Christine; Kuhn, Melissa; Forbes, Harper; Kim, Tae Min; Lee, Jeeyun; Demidov, Lev; Colburn, Dawn Journal: Journal of clinical pharmacology Issue: Volume 58:Number 8(2018) Page Start: 1067 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Issue 8 (August 2019) Authors: Long, Georgina V; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R; Maleski, Janet; Jones, Mark; Diede, Scott J; Mitchell, Tara C Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗